Investigación

Leucemia y hemopatías pediátricas

Buscador de publicaciones

Publicaciones

  • Perello C, Català-Temprano A, Caviedes L, Vega-García N, Camós-Guijosa M, Perez-Torras S and Pastor-Anglada M.

    FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia

    PHARMACOLOGICAL RESEARCH . 151: 104556-104556. Nº de citas: 5

    [doi:10.1016/j.phrs.2019.104556]

  • Pérez-Martínez A, Ferreras C, Pascual A, Gonzalez-Vicent M, Alonso L, Badell-Serra I, Navarro JMF, Regueiro A, Plaza M, Hurtado JMP, Benito A, Beléndez C, Couselo JM, Fuster JL, Díaz-Almirón M, Bueno D, Mozo Y, Marsal-Ricoma J, López AG, Sisinni L, de Heredia CD and Díaz MÁ.

    Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH).

    AMERICAN JOURNAL OF HEMATOLOGY . 95(1): 28-37. Nº de citas: 31

    [doi:10.1002/ajh.25661]

  • Pérez-Grijalba V, Arbizu J, Romero J, Prieto E, Pesini P, Sarasa L, Guillen F, Monleón I, San-José I, Martínez-Lage P, Munuera-del Cerro JL, Hernández I, Buendía M, Sotolongo-Grau O, Alegret M, Ruiz-Llobet A, Tárraga L, Boada M and Sarasa M.

    Plasma A beta 42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

    ALZHEIMERS RESEARCH & THERAPY . 11(1): 96-96. Nº de citas: 41

    [doi:10.1186/s13195-019-0549-1]

  • Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, De Moerloose B, Davis KL, Nemecek E, Driscoll T, Mechinaud F, Boissel N, Rives-Solà S, Bader P, Peters C, Sabnis HS, Grupp SA, Yanik GA, Hiramatsu H, Stefanski HE, Rasouliyan L, Yi L, Shah S, Zhang J and Harris AC.

    Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial

    LANCET ONCOLOGY . 20(12): 1710-1718. Nº de citas: 65

    [doi:10.1016/S1470-2045(19)30493-0]

  • Bautista F, Cañete A, Ramírez-Villar GL, Fernández JM, Fuster JL, Diaz de Heredia C, Astigarraga I, García-Ariza M, Rives-Solà S, Dapena JL, Márquez C, Molinés A, Bermúdez MDM, Gallego S, Andrés MDM, Verdu-Amoros J, Hernández C, López M, Català-Temprano A, Lassaletta Á, Cruz-Martínez O, Ramírez M, Lendínez F, Carboné A, Gomez Sirvent J, Tallón M, Acha T, Moreno L, Fernández-Teijeiro A and Sociedad Española de Hematología y Oncología Pediátrica (SEHOP).

    ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain

    CLINICAL & TRANSLATIONAL ONCOLOGY . 21(12): 1763-1770. Nº de citas: 4

    [doi:10.1007/s12094-019-02221-9]

  • Río P, Navarro S, Wang W, Sánchez-Domínguez R, Pujol RM, Segovia JC, Bogliolo M, Merino E, Wu N, Salgado R, Lamana ML, Yañez RM, Casado JA, Giménez Y, Román-Rodríguez FJ, Álvarez L, Alberquilla O, Raimbault A, Guenechea G, Lozano ML, Cerrato L, Hernando M, Gálvez E, Hladun R, Giralt I, Barquinero J, Galy A, García de Andoín N, López R, Català-Temprano A, Schwartz JD, Surrallés J, Soulier J, Schmidt M, Díaz de Heredia C, Sevilla J and Bueren JA.

    Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia.

    NATURE MEDICINE . 25(9): 1396-1401. Nº de citas: 107

    [doi:10.1038/s41591-019-0550-z]

  • Gonzalez-Farre B, Ramis-Zaldivar JE, Salmeron-Villalobos J, Balagué O, Celis-Passini V, Verdu-Amoros J, Nadeu F, Sábado C, Ferrández A, Garrido M, García-Bragado F, de la Maya MD, Vagace JM, Panizo CM, Astigarraga I, Andrés M, Jaffe ES, ELENA CAMPO and Salaverria I.

    Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.

    HAEMATOLOGICA . 104(9): 1822-1829. Nº de citas: 65

    [doi:10.3324/haematol.2018.207928]

  • Revilla N, Corral J, Miñano A, Mingot-Castellano ME, Campos RM, Velasco F, Gonzalez N, Galvez E, Berrueco R, Fuentes I, Gonzalez-Lopez TJ, de la Morena-Barrio ME, Gonzalez-Porras JR, Vicente V and Lozano ML.

    Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content

    Platelets . 30(6): 743-751. Nº de citas: 45

    [doi:10.1080/09537104.2018.1513476]

  • Monteagudo E, Astigarraga I, Cervera Á, Dasí MA, Sastre A, Berrueco R and Dapena JL.

    Protocol for the study and treatment of primary immune thrombocytopenia: ITP-2018

    ANALES DE PEDIATRIA . 91(2): . Nº de citas: 6

    [doi:10.1016/j.anpede.2019.04.008]

  • Gassiot S, González Y, Morgades M, Motlló C, Clapés V, Maluquer C, Ibarra G, Abril L, Ribera JM and Oriol A.

    Response to first cycle is the major predictor of long term response to lenalidomide and dexamethasone therapy in relapsed and refractory multiple myeloma: can we spare patients the toxicity and costs of additional agents?

    Clinical Lymphoma, Myeloma and Leukemia . : . Nº de citas: 2

    [doi:10.1016/j.clml.2019.05.020]